Journal Club

2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011

 

2021

Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study12.04.2021 (Pascal Urwyler)
Hansen C. H. et al.: Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study Lancet  397 1204–12 2021
Attributes and predictors of long COVID29.03.2021 (Aurélien Martinez)
Sudre C et al.: Attributes and predictors of long COVID Nature medicine 2021
Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study22.03.2021 (von Rotz Matthias)
Challen R. et al.: Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study BMJ 372:n579 1-10 2021
Comparable outcomes of short-course and prolonged-course therapy in selected cases of methicillin-susceptible Staphylococcus aureus bacteremia: A pooled cohort study15.03.2021 (Richard Kühl)
Louise Thorlacius-Ussing et al.: Comparable outcomes of short-course and prolonged-course therapy in selected cases of methicillin-susceptible Staphylococcus aureus bacteremia: A pooled cohort study CID Online ahead of print: 2021 Mar 2;ciab201.
doi: 10.1093/cid/ciab201. 2021
1) Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19
2) Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial
08.03.2021 (Silvio Ragozzino)
1) Gordon A.C. et al. 2) Horby P.W. et al.:
1) Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19
2) Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial

1) NEJM, February 25, 2021
2) MedRxiv (preprint), February 11, 2021
Efficacy and tolerability of quinacrine monotherapy and albendazole plus chloroquine combination therapy in nitroimidazole-refractory giardiasis: a TropNet study01.03.2021 (Andreas Neumayr)
Neumayr A. et al.: Efficacy and tolerability of quinacrine monotherapy and albendazole plus chloroquine combination therapy in nitroimidazole-refractory giardiasis: a TropNet study
1)    Do antibody positive healthcare workers have lower SARS-CoV-2 infection rates than antibody negative healthcare workers? Large multi-centre prospective cohort study (the SIREN study), England:4 June to November 2020
2)    Community prevalence of SARS-CoV-2 in England from April to November, 2020: results from the ONS Coronavirus Infection Survey
3)    The contribution of nosocomial infections to the first wave
22.02.2021 (Ana Durovic)
1)    Hall V et al
2)    Koen B Pouwels, Thomas House et al:
1)    Do antibody positive healthcare workers have lower SARS-CoV-2 infection rates than antibody negative healthcare workers? Large multi-centre prospective cohort study (the SIREN study), England:4 June to November 2020
2)    Community prevalence of SARS-CoV-2 in England from April to November, 2020: results from the ONS Coronavirus Infection Survey
3)    The contribution of nosocomial infections to the first wave

1)    medRxiv preprint: https://doi.org/10.1101/2021.01.13.21249642
2)    Lancet Public Health https://doi.org/10.1016/S2468-2667(20)30282-6
3)    63.+78. SAGE meeting on COVID-19
2021
Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: phase 3, randomised, controlled, non-inferiority trial15.02.2021 (Mihaela Sava)
Maertens JA et al.: Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: phase 3, randomised, controlled, non-inferiority trial The Lancet 397 499-509 2021
Interim Resukts of a Pahse 1-2a trial of Ad26.COV2.S Covid-19 Vaccine08.02.2021 (Anne-Valérie Burgener)
J. Sadoff et al.: Interim Resukts of a Pahse 1-2a trial of Ad26.COV2.S Covid-19 Vaccine NEJM Januray 13, 2021. DOI:10.1056/NEJMoa2034201 2021
Evaluation of Partial Oral Antibiotic Treatment for Persons Who Inject Drugs and Are Hospitalized With Invasive Infections01.02.2021 (Pascal Urwyler)
Marks L.R. et al.: Evaluation of Partial Oral Antibiotic Treatment for Persons Who Inject Drugs and Are Hospitalized With Invasive Infections Clinical Infectious Diseases 71(10) 650–6 2020
Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance25.01.2021 (Sabine Kuster)
Koehler P et al.: Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance Lancet Infect Dis Published online, December 14 1-14 2020
Treatment of Highly Drug-Resistant Pulmonary Tuberculosis18.01.2021 (Aurélien Martinez)
Francesca Conradie et al.: Treatment of Highly Drug-Resistant Pulmonary Tuberculosis
The New England Journal of Medicine 382 893-302 2021
Antibody Status and Inicidence of SARS-CoV-2 Infection in Health Care Workers11.01.2021 (Sandra Zingg)
Lumley S.F. et al: Antibody Status and Inicidence of SARS-CoV-2 Infection in Health Care Workers NEJM Decemeber 23, 2020